TRP_1170x120_12-19-19

Aurobindo Pharma USA Inc

Aurobindo’s Acrotech Biopharma to acquire oncology products from Spectrum Pharmaceuticals

Aurobindo’s Acrotech Biopharma to acquire oncology products from Spectrum Pharmaceuticals

EAST WINDSOR, N.J. — Aurobindo Pharma announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the U.S. Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., which in turn a wholly-owned subsidiary of Aurobindo Pharma

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

BASEL— Novartis today announced it has agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex